Computational Biology Market Growth, Analysis - Segmented by Application, Tools (Databases, Infrastructure (Hardware), Analysis Software & Services), Services, End-User and Geography - Trends, and Forecast (2018 - 2023)

  • ID: 4472847
  • Report
  • 147 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2018
1 of 5

FEATURED COMPANIES

  • Certara
  • Compugen Ltd
  • Dassault Systemes
  • Genedata AG
  • Insilico Biotechnology AG
  • Leadscope Inc
  • MORE
The global computational market was valued at USD 1,953.0 million in 2017, is expected to register a CAGR of about 19.54% during the forecast period, 2018-2023. Computational biology is defined as the application of mathematical models, theoretical methods and computer-aided simulation for the study of behavioural, social and biological systems. It is an interdisciplinary field, which includes the principles of applied mathematics, computer science, statistics, genomics, genetics, animation, visualization and a lot more. It makes use of biological data to construct relationship models and algorithms between different biological systems to analyze the differences and similarities among them. The various segments of the industry include computational genomics, computational neuroscience, computational bio-modelling, computational pharmacology, evolutionary biology and cancer research.

Increasing Number of Clinical Studies in Pharmacogenomics and Pharmacokinetics Boosts the Growth of Computational Biology Market

Pharmacogenomics testing is a step toward advancing clinical trials, new product development, and clinical practice. It permits drugs to be tailor-made for individual patients and studied as per generic makeup because some genes are responsible for the drug’s effect. This will likely help to create personalized medicine with greater efficacy and safety by understanding the genetic makeup of patients. Pharmacogenomics allows early identification of signals of predictive information, which doesn’t improve efficacy but provides useful information to the developers who are likely to be the responder, thus overall improving the drug development speed in clinical trials. Pharmacogenomic testing has become scalable and is being readily used. Pharmacogenomics is perfect for predicting antidepressant response and tolerability in the treatment of the major depressive disorder (MDD). In theory, pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. Pharmacogenomics study in cancer is a huge help in chemotherapy. Pharmacogenomic approaches have been applied to many existing chemotherapy agents in an effort to identify relevant inherited variations that may better predict patient response to chemotherapy. Thus, these pharmacogenomic studies are growing day by day, especially in the cancer field. Most of the developed nations and a majority of the people have already adopted the use of personalized medicine; this is happening especially in the cancer field. Moreover, in the coming years, all the developed and developing nations are expected to opt for personalized medicine. Thus, it is expected that pharmacogenomics and pharmacokinetics clinical studies are going to increase in the near future and this increasing clinical, in turn, will drive the computational biology market, as the computational biology is useful in the pharmacogenomics and pharmacokinetics clinical studies.

Lack of Trained Professionals Hinders the Growth of Computational Biology Market

Computational biology is an interdisciplinary and broad-ranging field, which harnesses the aspects of life science, computer science, mathematics, and statistics, to store, manage, and analyze biological data for the study of biological, behavioural, and social systems. The skill set required for computational biology is very diverse, and it continues to evolve. In the early days of the field, such as during the human genome project, it was sufficient to find homologous genes of one organism in the genome of another. However, as the field progressed, the processes became increasingly complex. Currently, computational biologists routinely compare multiple genomes while incorporating a host of proteomic information during bioinformatics studies. This is also done for the development of various cellular and biological simulations. The advent of high-throughput instrumentation has placed the growing volumes of biological data in the hands of both industry and academia. Computational biology is now intrinsic in the drug discovery process and other life science research. However, during the past decade, the field has witnessed a continuing deficiency in the expertise. In 2014, the Global Organization for Bioinformatics Learning, Education and Training (GOBLET) conducted a survey, which acquired feedback from more than 500 mathematicians, bioinformaticians, computer scientists, and biophysicists. Among these, nearly 64% considered themselves self-taught and acquired their skills via online courses, peer support, and professional workshops. Furthermore, more than 57% lacked confidence in their ability to use bioinformatics resources. While these surveys do not provide the complete picture of the computational biology industry as a whole, the survey results do highlight some consistency in the training gaps across the globe. Furthermore, owing to the relatively new age of the industry and the high interdisciplinary expertise requirement, there is a lack of trained personnel in the industry, which can result in a restrained growth of the market.

Market Segmentation Insights for the Computational Biology Market

Insights from the application segment which is further segmented into Cellular & Biological Simulation, Drug Discovery and Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software. Drug discovery has the largest share in the market which is about 52% as computational biology will help predict drug effects in patients, enabling personalized medicine, improvement of the success rate of new drugs in the clinic, and the finding of new uses for existing drugs. However, Clinical trials have the highest CAGR 19.83% during the forecast period.

Insights into the tools segment which is further divided into Databases, Infrastructure (Hardware) and Analysis Software & Services. Analysis Software & Services dominating the market in tools due to the increased government initiatives in order to develop reliable database systems. For instance, the Government of India through the Department of Biotechnology (DBT), have created a setup of distributed information centre & research facility across the country with the help of Biotechnology Information System Network (BTISnet). It has the highest CAGR in the computational biology market.

By services, the market is segmented into In-House and Contract. Contract Services are dominating the market by 61.4% share as they are less expensive, as compared to the in-house services, they provide just-in-time delivery with a single point of contact, and give access to a wide range of industry software.

In the end-user segment, it is segmented into Academics, Industry and Commercial. The commercial has the largest share in the market about 46% in 2017. Increase in bioinformatics research, the increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and the growth of drug designing, disease modelling, and personalized medicine, the demand for computational biology for commercial purposes is expected to increase, further driving the market during the forecast period. The industry has the highest CAGR in the end-user during the forecast period.

North America to Dominate the Computational Biology Market

North America dominates the market due to growing initiatives and investments for R&D of drug discovery, novel drugs, disease modelling, and technological advancements in biological computations. Furthermore, the US government channelled more than USD 1 billion for the development of computational biology and synthetic biology. Annual average expenditure for the development of computational biology, by the US government, has been estimated to be 140 million USD. In 2016, the Parliamentary Secretary to the Minister of International Development, Karina Gould, on behalf of the Minister of Science, Kirsty Duncan, announced an investment of 4 million USD in 16 new bioinformatics and computational biology (B/CB) research projects to be conducted at academic institutions across Canada. The market for computational biology in Canada is expected to grow substantially, over the forecast period, primarily due to increasing interest from the Canadian government in the development of computational biology.

Key Developments in the Market
  • Feb 2018 - Certara has recently acquired BaseCase, a Life Sciences Data Visualization company.
  • Feb 2018 - Schrödinger launched Cryo-EM Initiative (SCI) to develop breakthrough medicines using cryo-electron microscopy (Cryo-EM) technology.
Major Players: Dassault Systemes, Certara, Chemical Computing Group Inc., Compugen Ltd, Rosa & Co LLC, Genedata AG, Insilico Biotechnology AG, Leadscope Inc, Nimbus Discovery LLC, Strand Life Sciences, Schrodinger, Simulation Plus Inc among others.

Reasons to Purchase the Report
  • Current and future of Computational Biology market outlook in the developed and emerging markets
  • Analysis of various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 month analyst support, along with the market estimate sheet (in Excel)
Customization of the Computational Biology Market Report
  • This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Certara
  • Compugen Ltd
  • Dassault Systemes
  • Genedata AG
  • Insilico Biotechnology AG
  • Leadscope Inc
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities And Challenges Analysis (Droc)
6.1 Market Drivers
6.1.1 Increase in Bioinformatics Research
6.1.2 Increasing Number of Clinical Studies in Pharmacogenomics and Pharmacokinetics
6.1.3 Growth of Drug Designing, Disease Modeling, and Personalized Medicine
6.2 Market Restraints
6.2.1 Lack of Trained Professional
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Application
7.1.1 Cellular & Biological Simulation
7.1.1.1 Computational Genomics
7.1.1.2 Computational Proteomics
7.1.1.3 Pharmacogenomics
7.1.1.4 Other Cellular and Biological Simulations (Transcriptomics/Metabolomics)
7.1.2 Drug Discovery and Disease Modelling
7.1.2.1 Target Identification
7.1.2.2 Target Validation
7.1.2.3 Lead Discovery
7.1.2.4 Lead Optimization
7.1.3 Preclinical Drug Development
7.1.3.1 Pharmacokinetics
7.1.3.2 Pharmacodynamics
7.1.4 Clinical Trials
7.1.4.1 Phase I
7.1.4.2 Phase II
7.1.4.3 Phase III
7.1.5 Human Body Simulation Software
7.2 By Tools
7.2.1 Databases
7.2.2 Infrastructure(Hardware)
7.2.3 Analysis Software & Services
7.3 By Services
7.3.1 In-House
7.3.2 Contract
7.4 By End - User
7.4.1 Academics
7.4.2 Industry
7.4.3 Commercial
7.5 By Geography
7.5.1 North America
7.5.1.1 United States
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 United Kingdom
7.5.2.3 Germany
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 India
7.5.3.2 China
7.5.3.3 Japan
7.5.3.4 Australia
7.5.3.5 South Korea
7.5.3.6 Rest of APAC
7.5.4 Middle East & Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of Middle East & Africa
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers And Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches

9. Major Players
9.1 Dassault Systemes
9.2 Certara
9.3 Chemical Computing Group Inc.
9.4 Compugen Ltd
9.5 Rosa & Co. LLC (Acquired Entelos)
9.6 Genedata AG
9.7 Insilico Biotechnology AG
9.8 Leadscope Inc
9.9 Nimbus Discovery Llc
9.10 Strand Life Sciences
9.11 Schrodinger
9.12 Simulation Plus Inc

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Dassault Systemes
  • Certara
  • Chemical Computing Group Inc.
  • Compugen Ltd
  • Rosa & Co. LLC (Acquired Entelos)
  • Genedata AG
  • Insilico Biotechnology AG
  • Leadscope Inc
  • Nimbus Discovery Llc
  • Strand Life Sciences
  • Schrodinger
  • Simulation Plus Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll